SCB-313 (TRAIL-Trimer): Oncology

SCB-313 is a novel fusion protein consisting of TRAIL (TNF-related apoptosis-inducing ligand) and our proprietary Trimer-Tag©, allowing TRAIL to form a stable covalently-trimerized complex. TRAIL and its receptors, which are selectively expressed on many tumors, must be trimerized in order to trigger the programmed cell death signaling pathway.

In preclinical studies, SCB-313 has demonstrated potent ability to induce apoptosis in multiple human tumor models with a favorable safety profile. It has also demonstrated multi-fold superior potency compared to a dimeric TRAIL agonist.

SCB-313 is currently in Phase I clinical testing in Australia and China.